Shilpa Medicare gets USFDA EIR for Raichur API Unit

Written by Ruchika Sharma Published On 2020-04-21T12:07:25+05:30 | Updated On 21 April 2020 12:07 PM IST

Shilpa Medicare gets USFDA EIR for Raichur API Unit

Raichur: Shilpa Medicare Limited has announced the receipt of Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at API manufacturing site located at Raichur, Karnataka, India during the period between "03rd February and 07th February 2020". USFDA has determined that the inspection classification of this facility is "NO ACTION INDICATED" ("NAI").

Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India.

The commercial production in the SML was started in November 1989.

shilpa-medicareusfda

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751